Brazil Androgenetic Alopecia Market Size & Outlook
The androgenetic alopecia market in Brazil is expected to reach a projected revenue of US$ 56.0 million by 2030. A compound annual growth rate of 9.1% is expected of Brazil androgenetic alopecia market from 2024 to 2030.
The Brazil androgenetic alopecia market generated a revenue of USD 30.4 million in 2023 and is expected to reach USD 56.0 million by 2030.
The Brazil market is expected to grow at a CAGR of 9.1% from 2024 to 2030.
In terms of segment, pharmaceuticals was the largest revenue generating treatment in 2023.
Devices is the most lucrative treatment segment registering the fastest growth during the forecast period.
Androgenetic alopecia market data book summary
Market revenue in 2023
USD 30.4 million
Market revenue in 2030
USD 56.0 million
Growth rate
9.1% (CAGR from 2023 to 2030)
Largest segment
Pharmaceuticals
Fastest growing segment
Devices
Historical data
2018 - 2022
Base year
2023
Forecast period
2024 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Pharmaceuticals, Devices
Key market players worldwide
Johnson & Johnson, Cipla Ltd DR, Sun Pharmaceutical Industries, Merck & Co Inc, Dr. Reddy’s Laboratories, Cardiff Lexington Corp, Amgen Inc, Theradome, Aurobindo Pharma, Curallux, Apira Science
Other key industry trends
In terms of revenue, Brazil accounted for 1.1% of the global androgenetic alopecia market in 2023.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In Latin America, Brazil androgenetic alopecia market is projected to lead the regional market in terms of revenue in 2030.
Mexico is the fastest growing regional market in Latin America and is projected to reach USD 24.2 million by 2030.
Moreover, the increasing geriatric population and awareness among the general population are considered to be a major driver fueling market growth. For instance, in 2022, the country’s overall population aged 65 & above was around 21.26 million, and it is expected to increase in the coming decade.
According to a survey conducted by GSK plc, around 70.9% of AGA patients preferred OTC medications, in which 33.2% of the patients used 5-ARI followed by minoxidil, which was used by 28.6% of the total patients. In Brazil, medication is the most frequently used treatment for androgenetic alopecia.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Androgenetic Alopecia Market Outlook will help companies and investors design strategic landscapes.
Pharmaceuticals was the largest segment with a revenue share of 98.68% in 2023.
Horizon Databook has segmented the Brazil androgenetic alopecia market based on pharmaceuticals, devices covering the revenue growth of each sub-segment from 2018 to 2030.
Moreover, the increasing geriatric population and awareness among the general population are considered to be a major driver fueling market growth. For instance, in 2022, the country’s overall population aged 65 & above was around 21.26 million, and it is expected to increase in the coming decade.
According to a survey conducted by GSK plc, around 70.9% of AGA patients preferred OTC medications, in which 33.2% of the patients used 5-ARI followed by minoxidil, which was used by 28.6% of the total patients. In Brazil, medication is the most frequently used treatment for androgenetic alopecia.
Brazil Androgenetic Alopecia Market Treatment Outlook (Revenue, USD MIllion , 2018-2030)
Pharmaceuticals
Devices
Brazil Androgenetic Alopecia Market End-use Outlook (Revenue, USD MIllion , 2018-2030)
Homecare Settings
Dermatology Clinics
Brazil Androgenetic Alopecia Market Sales Channel Outlook (Revenue, USD MIllion , 2018-2030)
Prescriptions
OTC
Brazil Androgenetic Alopecia Market Gender Outlook (Revenue, USD MIllion , 2018-2030)
Male
Female
Reasons to subscribe to Androgenetic Alopecia Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Androgenetic Alopecia Market Outlook databook
Our clientele includes a mix of Androgenetic Alopecia Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil Androgenetic Alopecia Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Brazil Androgenetic Alopecia Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Brazil Androgenetic Alopecia Market, 2018-2030 (US$M)